AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35980238 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal Adhesive (SB; universal) with two coats
Number of subjects: 99
Study 35980238 — intervention group
Group type: EXPERIMENTAL
Intervention: G Premio Bond (GP; universal) with two coats
Number of subjects: 99
Study 35980238 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Megabond 2 (MB; two-step self-etch; control) with two coats
Number of subjects: 99
Study 34437779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 14
Study 34437779 — intervention group
Group type: COMPARATOR
Intervention: Sham Treatment
Number of subjects: 14
Study 32017994 — intervention group
Group type: EXPERIMENTAL
Intervention: IDWL+3 weeks of coaching ('Brief')
Number of subjects: 450
Study 32017994 — intervention group
Group type: EXPERIMENTAL
Intervention: IDWL+12 weeks of coaching ('Extended')
Number of subjects: 450
Study 32017994 — intervention group
Group type: COMPARATOR
Intervention: IDWL only ('Control')
Number of subjects: 450
Study 34675401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium lentil diet
Number of subjects: 405
Study 34675401 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 405
Study 35387686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet‐placebo (hypocaloric diet + placebo supplementation)
Number of subjects: 97
Study 35387686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet‐fish (hypocaloric diet + 3 g/day of omega‐3 supplementation)
Number of subjects: 97
Study 35387686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 34418550 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera (WS)
Number of subjects: 400
Study 34418550 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 400
Study 36287566 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin administration (75-minute intravenous infusion of kisspeptin-54 at 1 nmol/kg/h)
Number of subjects: 40
Study 36469965 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted gluteal intervention
Number of subjects: 22
Study 36029059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60
Study 36029059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day for 22 weeks)
Number of subjects: 60
Study 36029059 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 60
Study 33113526 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 U/kg Epo intravenously for 6 doses, followed by 400 U/kg Epo subcutaneously 3 times a week through 32 weeks post-menstrual age
Number of subjects: 941
Study 33113526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 36078778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program using home floor plans; evaluated effectiveness six months after discharge.
Number of subjects: 60
Study 36078778 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy for disease characteristics; control group treatment before discharge.
Number of subjects: 60
Study 34021703 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-Score
Number of subjects: 0
Study 34021703 — intervention group
Group type: COMPARATOR
Intervention: ML-based scoring functions
Number of subjects: 0
Study 34021703 — intervention group
Group type: COMPARATOR
Intervention: Classical scoring functions
Number of subjects: 0
Study 35734895 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte‐ and platelet‐rich fibrin (L‐PRF) application
Number of subjects: 18
Study 35734895 — intervention group
Group type: COMPARATOR
Intervention: Unassisted healing
Number of subjects: 18
Study 35734895 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐PRF application
Number of subjects: 18
Study 33644963 — intervention group
Group type: EXPERIMENTAL
Intervention: PNT
Number of subjects: 40
Study 33644963 — intervention group
Group type: COMPARATOR
Intervention: PNT + LR-PRP
Number of subjects: 40
Study 34299891 — intervention group
Group type: EXPERIMENTAL
Intervention: 33-week swimming program
Number of subjects: 22
Study 34299891 — intervention group
Group type: COMPARATOR
Intervention: Normal daily activity (Control)
Number of subjects: 22
Study 32414547 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin administered to the levator labii superioris alaeque nasi muscle (Group 1)
Number of subjects: 28
Study 32414547 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin administered to the orbicularis oris site (Group 2)
Number of subjects: 28
Study 32414547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 35787043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 35787043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32000853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to risk factors (independent variables such as maternal age, gravidity, parity, antenatal visits, booking status, marital status, educational status, days spent in hospital, mode of delivery, fetal outcomes, and maternal complications)
Number of subjects: 387
Study 32000853 — intervention group
Group type: COMPARATOR
Intervention: Control group (women of child-bearing age who survived during the study period)
Number of subjects: 387
Study 34453675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 2969
Study 34453675 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 2969
Study 34760995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan therapy during 6-minute walk test (6MWT)
Number of subjects: 14
Study 34760995 — intervention group
Group type: COMPARATOR
Intervention: No fan therapy during 6-minute walk test (6MWT)
Number of subjects: 14
Study 35984123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride injection (0.08 mg/kg)
Number of subjects: 0
Study 34125148 — intervention group
Group type: EXPERIMENTAL
Intervention: New respiratory support system with short binasal prongs (n = 124 infants)
Number of subjects: 246
Study 34125148 — intervention group
Group type: COMPARATOR
Intervention: Standard T‐piece system with face mask (n = 122 infants)
Number of subjects: 246
Study 32340869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy care-map implemented after the intervention.
Number of subjects: 78
Study 32340869 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest physiotherapy before the care-map implementation.
Number of subjects: 78
Study 35491328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouth rinse (FMR) group: 0.2% sodium fluoride mouth rinse plus 1450 ppm fluoride toothpaste
Number of subjects: 255
Study 35491328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluoride toothpaste (HFT) group: 5000 ppm fluoride toothpaste
Number of subjects: 255
Study 35491328 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR) group: 1450 ppm fluoride toothpaste
Number of subjects: 255
Study 32862595 — intervention group
Group type: EXPERIMENTAL
Intervention: etoposide + lobaplatin (EL group)
Number of subjects: 98
Study 32862595 — intervention group
Group type: COMPARATOR
Intervention: etoposide + cisplatin (EP group)
Number of subjects: 98
Study 35987885 — intervention group
Group type: EXPERIMENTAL
Intervention: mirabegron 25 mg once per day for 12 weeks
Number of subjects: 87
Study 35987885 — intervention group
Group type: COMPARATOR
Intervention: solifenacin 5 mg once per day for 12 weeks
Number of subjects: 87
Study 32390724 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 34
Study 32390724 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 34
Study 35288248 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incision negative pressure therapy (ciNPT)
Number of subjects: 0
Study 35288248 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 35088602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined early palliative care (CEPC)
Number of subjects: 120
Study 35088602 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care (SC)
Number of subjects: 120
Study 33270306 — intervention group
Group type: EXPERIMENTAL
Intervention: VASCADE® venous vascular closure system (VVCS)
Number of subjects: 168
Study 33270306 — intervention group
Group type: EXPERIMENTAL
Intervention: No urinary catheter (UC)
Number of subjects: 168
Study 33270306 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin without protamine reversal
Number of subjects: 168
Study 33270306 — intervention group
Group type: EXPERIMENTAL
Intervention: Same calendar day discharge (SCDD)
Number of subjects: 168
Study 33270306 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 168
Study 32715449 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser
Number of subjects: 35
Study 32715449 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURBT
Number of subjects: 35
Study 32703098 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-practice (hybrid practice schedule with forward/backward switching based on error trial number)
Number of subjects: 60
Study 32703098 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked-practice
Number of subjects: 60
Study 32703098 — intervention group
Group type: COMPARATOR
Intervention: Random-practice
Number of subjects: 60
Study 32703098 — intervention group
Group type: COMPARATOR
Intervention: Dissimilar conditions (blocked, algorithm, random)
Number of subjects: 60
Study 32703098 — intervention group
Group type: COMPARATOR
Intervention: Similar conditions (blocked, algorithm, random)
Number of subjects: 60
Study 36170895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway
Number of subjects: 0
Study 36170895 — intervention group
Group type: COMPARATOR
Intervention: Conventional care pathway
Number of subjects: 0
Study 36170895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with 30% drug discount
Number of subjects: 0
Study 36170895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with 60% drug discount
Number of subjects: 0
Study 36170895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with 90% drug discount
Number of subjects: 0
Study 36170895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led pathway with re-infection rates of 8/5/2 per 100 person-years
Number of subjects: 0
Study 34086176 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to indoor air pollutants (PM2.5, CO, BC)
Number of subjects: 68
Study 34086176 — intervention group
Group type: COMPARATOR
Intervention: Biomass used for cooking
Number of subjects: 68
Study 32599767 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based physical activity promotion for 3 months after rehabilitation
Number of subjects: 64
Study 32599767 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based physical activity promotion
Number of subjects: 64
Study 32599767 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 64
Study 34578798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with monosodium glutamate (MSG) at 2.7 g/day during the second round of chemotherapy
Number of subjects: 0
Study 34578798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MSG supplementation)
Number of subjects: 0
Study 33051035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 5
Study 33051035 — intervention group
Group type: EXPERIMENTAL
Intervention: Countering emotional behaviors
Number of subjects: 5
Study 35201806 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day marijuana deprivation (N = 68)
Number of subjects: 210
Study 35201806 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing heavy marijuana use (N = 66)
Number of subjects: 210
Study 35201806 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthoc analyses on startle reactivity × deprivation interaction
Number of subjects: 210
Study 35769355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin (30 mg/m²) added to docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Number of subjects: 200
Study 35769355 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m²) and epirubicin (80 mg/m²) every 3 weeks for four cycles, followed by two cycles post-surgery.
Number of subjects: 200
Study 35769355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin (30 mg/m²) added to docetaxel and epirubicin.
Number of subjects: 200
Study 35769355 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and epirubicin without lobaplatin.
Number of subjects: 200
Study 35769355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobaplatin added to chemotherapy.
Number of subjects: 200
Study 33077331 — intervention group
Group type: EXPERIMENTAL
Intervention: Open fire with biomass fuel for cooking (85.8% of households)
Number of subjects: 2713
Study 33077331 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with an older sibling ≥12 years
Number of subjects: 2713
Study 33077331 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age of children
Number of subjects: 2713
Study 616507939 — intervention group
Group type: EXPERIMENTAL
Intervention: UMUST (Unexpected Medical Undergraduate Simulation Training)
Number of subjects: 0
Study 35462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Time in Range (TIR) with Glycemic Management Indicator (GMI) at a fixed GMI value of 7%
Number of subjects: 83
Study 35462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of CV (≤35.91%)
Number of subjects: 83
Study 35462500 — intervention group
Group type: EXPERIMENTAL
Intervention: 25th-50th quartile of CV (35.91%<CV≤40.08%)
Number of subjects: 83
Study 35462500 — intervention group
Group type: EXPERIMENTAL
Intervention: 50th-75th quartile of CV (40.08%<CV≤45.86%)
Number of subjects: 83
Study 35462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of CV (>75th quartile, CV>45.86%)
Number of subjects: 83
Study 35462500 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TIR and GMI
Number of subjects: 83
Study 35277067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI MED-HEP
Number of subjects: 160
Study 35277067 — intervention group
Group type: COMPARATOR
Intervention: High-GI MED-HEP
Number of subjects: 160
Study 33693494 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg SHR4640
Number of subjects: 197
Study 33693494 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg SHR4640
Number of subjects: 197
Study 33693494 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg benzbromarone
Number of subjects: 197
Study 33693494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 32757339 — intervention group
Group type: EXPERIMENTAL
Intervention: Short waiters (≤ 18 weeks)
Number of subjects: 203
Study 32757339 — intervention group
Group type: COMPARATOR
Intervention: Long waiters (> 18 weeks)
Number of subjects: 203
Study 32757339 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in waiting time by a week
Number of subjects: 203
Study 35727844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided transversus abdominis plane (UTAP)
Number of subjects: 143
Study 35727844 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted transversus abdominis plane (RTAP)
Number of subjects: 143
Study 35727844 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia (LA)
Number of subjects: 143
Study 32312313 — intervention group
Group type: EXPERIMENTAL
Intervention: Word version of the manuscript
Number of subjects: 602
Study 32312313 — intervention group
Group type: EXPERIMENTAL
Intervention: PDF version of the manuscript
Number of subjects: 602
Study 32312313 — intervention group
Group type: EXPERIMENTAL
Intervention: All journals
Number of subjects: 602
Study 616501576 — intervention group
Group type: EXPERIMENTAL
Intervention: Common three‐dose intramuscular priming series followed by a final booster at 6 months
Number of subjects: 12
Study 616501576 — intervention group
Group type: EXPERIMENTAL
Intervention: Common three‐dose intramuscular priming series followed by a final booster at 12 months
Number of subjects: 12
Study 616501576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine regimens
Number of subjects: 12
Study 34824000 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 treatment over the protective face mask
Number of subjects: 40
Study 34824000 — intervention group
Group type: COMPARATOR
Intervention: Protective face mask worn over the O2 delivery system
Number of subjects: 40
Study 33871845 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32669132 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise training
Number of subjects: 0
Study 32669132 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 33810996 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory rehabilitation using four different odors applied orthonasally for 30 min per day for 6 months
Number of subjects: 11
Study 33160695 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 203
Study 33160695 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 203
Study 32913210 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP + LMA
Number of subjects: 96
Study 32913210 — intervention group
Group type: COMPARATOR
Intervention: Control (General anesthesia with endotracheal intubation)
Number of subjects: 96
Study 32913210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 36124652 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary choline intake (Q4)
Number of subjects: 5613
Study 36124652 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary betaine intake (Q4)
Number of subjects: 5613
Study 35119213 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic cannulae
Number of subjects: 8
Study 35119213 — intervention group
Group type: COMPARATOR
Intervention: Metal needles
Number of subjects: 8
Study 35912143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma globulin combined with azithromycin sequential therapy
Number of subjects: 100
Study 35912143 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin plus comprehensive basic treatment
Number of subjects: 100
Study 34138667 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐1 injections combined with HSR training
Number of subjects: 40
Study 34138667 — intervention group
Group type: COMPARATOR
Intervention: Saline injections combined with HSR training
Number of subjects: 40
Study 33795978 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed hypertension
Number of subjects: 378
Study 33795978 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed type 2 diabetes (T2D)
Number of subjects: 378
Study 33795978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both undiagnosed hypertension and undiagnosed T2D
Number of subjects: 378
Study 33795978 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed T2D
Number of subjects: 378
Study 32413431 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable anchors
Number of subjects: 53
Study 32413431 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 53
Study 33583341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 40 mg
Number of subjects: 30
Study 33583341 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 33933236 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐CONT (continuation of first-line fluorouracil/platinum-based chemotherapy)
Number of subjects: 67
Study 33933236 — intervention group
Group type: COMPARATOR
Intervention: CT‐DISC (discontinuation of first-line chemotherapy)
Number of subjects: 67
Study 33336218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gantenerumab 1200 mg every 4 weeks
Number of subjects: 0
Study 33336218 — intervention group
Group type: COMPARATOR
Intervention: Marguerite RoAD double-blind placebo
Number of subjects: 0
Study 33336218 — intervention group
Group type: EXPERIMENTAL
Intervention: Marguerite RoAD double-blind active
Number of subjects: 0
Study 34657856 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted trunk control training (RT group)
Number of subjects: 40
Study 34657856 — intervention group
Group type: COMPARATOR
Intervention: Conventional trunk stabilization training + stretching exercise (Control group)
Number of subjects: 40
Study 34912120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus trastuzumab and chemotherapy
Number of subjects: 0
Study 34912120 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 0
Study 32723330 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency obstetric simulation-based training program
Number of subjects: 7
Study 35094447 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5% after TCA-CROSS
Number of subjects: 45
Study 35094447 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline injection before TCA-CROSS
Number of subjects: 45
Study 35094447 — intervention group
Group type: COMPARATOR
Intervention: TCA-CROSS alone
Number of subjects: 45
Study 35094447 — intervention group
Group type: COMPARATOR
Intervention: Saline + TCA-CROSS
Number of subjects: 45
Study 35094447 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction in groups 2 and 3
Number of subjects: 45
Study 33625665 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine stopped at 7 days apnea-free period
Number of subjects: 120
Study 33625665 — intervention group
Group type: COMPARATOR
Intervention: Caffeine continued until at least 34 weeks postmenstrual age (PMA)
Number of subjects: 120
Study 32513288 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided dosage adjustments of docetaxel-based chemotherapy
Number of subjects: 209
Study 32513288 — intervention group
Group type: COMPARATOR
Intervention: BSA-guided dosage adjustments of docetaxel-based chemotherapy
Number of subjects: 209
Study 34725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth and family members as full members of the project team, including project leadership and governance.
Number of subjects: 0